A new era for equity in meningococcal disease prevention
- PMID: 37579772
- DOI: 10.1016/S1473-3099(23)00232-3
A new era for equity in meningococcal disease prevention
Conflict of interest statement
HM is an investigator on clinical vaccine trials sponsored by GlaxoSmithKline, Sanofi-Pasteur, and Pfizer. BW and HM receive funding via their institutions for investigator-led research from GlaxoSmithKline, Pfizer, and Sanofi-Pasteur.
Comment on
-
Immunogenicity and safety of a pentavalent meningococcal ABCWY vaccine in adolescents and young adults: an observer-blind, active-controlled, randomised trial.Lancet Infect Dis. 2023 Dec;23(12):1370-1382. doi: 10.1016/S1473-3099(23)00191-3. Epub 2023 Aug 11. Lancet Infect Dis. 2023. PMID: 37579773 Clinical Trial.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
